HUTCHMED (China)

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Movers_Stocks

News

Intraday Update

Markets

Movers

Trading Ideas

ALMS

CRWV

LZMH

MVST

NMAX

NYAX

OKLO

PRGS

Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Earnings

Guidance

Health Care

General

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and new regulatory approvals in China.

Hutchmed&#39;s Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025.

Chinese Cancer Drug Developer Hutchmed Sharpens R&amp;D Focus, Divests Non-Core JV For Over $600 Million

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Press Releases

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Management

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

ABBNY

BDOUY

BLTE

BVNRY

CLCGY

EPOAY

FPAFY

ICAGY

IFNNY

VIOT

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Axsome Therapeutics

BGM Group

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Indivior

Innoviva

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Comments

HUTCHMED (China)

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell